ROADMAP and ORIENTAL Trials: the Re-emergence of J-Curve Ghost?

It still remains unknown whether angiotensin-receptor blockers (ARBs) are cardioprotective in patients with type 2 diabetes. The recent two clinical trials, the ROADMAP and the ORIENT, have suggested that fatal cardiovascular events or cardiovascular deaths were unexpectedly higher in olmesartan gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamamoto, Yoshiyuki, Koshiyama, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2011
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699452/
https://www.ncbi.nlm.nih.gov/pubmed/23885187
http://dx.doi.org/10.4137/JCM.S7521
_version_ 1782275387034697728
author Hamamoto, Yoshiyuki
Koshiyama, Hiroyuki
author_facet Hamamoto, Yoshiyuki
Koshiyama, Hiroyuki
author_sort Hamamoto, Yoshiyuki
collection PubMed
description It still remains unknown whether angiotensin-receptor blockers (ARBs) are cardioprotective in patients with type 2 diabetes. The recent two clinical trials, the ROADMAP and the ORIENT, have suggested that fatal cardiovascular events or cardiovascular deaths were unexpectedly higher in olmesartan group. These results suggest that aggressive blood pressure lowering may cause a higher risk in some high-risk patients, especially in those with preexisting coronary heart disease, indicating a possibility that the J-curve phenomenon may exist in some group of patients.
format Online
Article
Text
id pubmed-3699452
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-36994522013-07-24 ROADMAP and ORIENTAL Trials: the Re-emergence of J-Curve Ghost? Hamamoto, Yoshiyuki Koshiyama, Hiroyuki Jpn Clin Med Editorial It still remains unknown whether angiotensin-receptor blockers (ARBs) are cardioprotective in patients with type 2 diabetes. The recent two clinical trials, the ROADMAP and the ORIENT, have suggested that fatal cardiovascular events or cardiovascular deaths were unexpectedly higher in olmesartan group. These results suggest that aggressive blood pressure lowering may cause a higher risk in some high-risk patients, especially in those with preexisting coronary heart disease, indicating a possibility that the J-curve phenomenon may exist in some group of patients. Libertas Academica 2011-06-19 /pmc/articles/PMC3699452/ /pubmed/23885187 http://dx.doi.org/10.4137/JCM.S7521 Text en © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Editorial
Hamamoto, Yoshiyuki
Koshiyama, Hiroyuki
ROADMAP and ORIENTAL Trials: the Re-emergence of J-Curve Ghost?
title ROADMAP and ORIENTAL Trials: the Re-emergence of J-Curve Ghost?
title_full ROADMAP and ORIENTAL Trials: the Re-emergence of J-Curve Ghost?
title_fullStr ROADMAP and ORIENTAL Trials: the Re-emergence of J-Curve Ghost?
title_full_unstemmed ROADMAP and ORIENTAL Trials: the Re-emergence of J-Curve Ghost?
title_short ROADMAP and ORIENTAL Trials: the Re-emergence of J-Curve Ghost?
title_sort roadmap and oriental trials: the re-emergence of j-curve ghost?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699452/
https://www.ncbi.nlm.nih.gov/pubmed/23885187
http://dx.doi.org/10.4137/JCM.S7521
work_keys_str_mv AT hamamotoyoshiyuki roadmapandorientaltrialsthereemergenceofjcurveghost
AT koshiyamahiroyuki roadmapandorientaltrialsthereemergenceofjcurveghost

Ejemplares similares